drugset
drugset / Trial / NCT03388372

Nimotuzumab Plus Radiotherapy With Concomitant and Adjuvant Temozolomide for Cerebral Glioblastoma

NCT03388372 ↗

Phase 2 Completed 39 enrolled Biotech Pharmaceutical Co., Ltd. Sun Yat-sen University · collab
NaSingle-groupOpen-labelTreatment

Summary

This study aimed to investigate the clinical benefit contribution and safety of nimotuzumab to the standard combined treatment for patients with newly diagnosed glioblastoma.

Timeline

Start
2010-08-18
Primary completion
2017-03-23
Completion
2017-03-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Nimotuzumab Monoclonal antibody 200 mg Intravenous
Background Temozolomide Small molecule 150 mg/m2 Oral
Background Temozolomide Small molecule 200 mg/m2 Oral

Indications

glioblastoma